Literature DB >> 16002428

The kinetics of clonal dominance in myeloproliferative disorders.

Sandra N Catlin1, Peter Guttorp, Janis L Abkowitz.   

Abstract

To study clonal evolution in myeloproliferative disorders, we used stochastic models of hematopoiesis for mouse and cat, species for which the in vivo kinetics of hematopoietic stem cells (HSCs) have been experimentally defined. We determined the consequence if 1 HSC became able to survive without the support of a microenvironmental niche while the rest of its behavior did not change. Neoplastic cells persisted and dominated hematopoiesis in 14% of mice and 17% of cats, requiring mean times of 2.5 +/- 0.5 and 7.0 +/- 1.2 years, respectively (n=1000 simulations/species). In both species, when the number of neoplastic HSCs exceeded 0.5% of all HSCs, clonal dominance was inevitable. Our results can explain the absence of clonal myeloproliferative disorders in mice (lifetime, 2 years), are consistent with clinical observations in cats, and provide insight into the progression of chronic myelogenous leukemia (CML) in humans. They also demonstrate that competition for microenvironmental support can lead to the suppression of normal hematopoiesis as neoplasia evolves. Toxic or immunologic suppression of normal HSCs is not required.

Entities:  

Mesh:

Year:  2005        PMID: 16002428      PMCID: PMC1895315          DOI: 10.1182/blood-2005-03-1240

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

Review 1.  The biology of chronic myeloid leukemia.

Authors:  S Faderl; M Talpaz; Z Estrov; S O'Brien; R Kurzrock; H M Kantarjian
Journal:  N Engl J Med       Date:  1999-07-15       Impact factor: 91.245

2.  In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells.

Authors:  S H Cheshier; S J Morrison; X Liao; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

Review 3.  On the molecular origins of the chronic myeloproliferative disorders: it all makes sense.

Authors:  Kenneth Kaushansky
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

4.  Hematologic abnormalities and outcome of 16 cats with myelodysplastic syndromes.

Authors:  M Hisasue; H Okayama; T Okayama; T Suzuki; T Mizuno; Y Fujino; K Naganobu; A Hasegawa; T Watari; N Matsuki; K Masuda; K Ohno; H Tsujimoto
Journal:  J Vet Intern Med       Date:  2001 Sep-Oct       Impact factor: 3.333

5.  Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment.

Authors:  G B Bradford; B Williams; R Rossi; I Bertoncello
Journal:  Exp Hematol       Date:  1997-05       Impact factor: 3.084

Review 6.  Myelopoiesis and myeloproliferative disorders.

Authors:  R E Raskin
Journal:  Vet Clin North Am Small Anim Pract       Date:  1996-09       Impact factor: 2.093

7.  In vivo kinetics of murine hemopoietic stem cells.

Authors:  J L Abkowitz; D Golinelli; D E Harrison; P Guttorp
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

8.  Evidence that the number of hematopoietic stem cells per animal is conserved in mammals.

Authors:  Janis L Abkowitz; Sandra N Catlin; Monica T McCallie; Peter Guttorp
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

9.  Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals.

Authors:  C Biernaux; M Loos; A Sels; G Huez; P Stryckmans
Journal:  Blood       Date:  1995-10-15       Impact factor: 22.113

Review 10.  Human hematopoietic lineage commitment.

Authors:  Kimberly J Payne; Gay M Crooks
Journal:  Immunol Rev       Date:  2002-09       Impact factor: 12.988

View more
  17 in total

1.  Somatic and germline genetics at the JAK2 locus.

Authors:  Peter J Campbell
Journal:  Nat Genet       Date:  2009-04       Impact factor: 38.330

2.  Clonal hematopoiesis: mechanisms driving dominance of stem cell clones.

Authors:  Grant A Challen; Margaret A Goodell
Journal:  Blood       Date:  2020-10-01       Impact factor: 22.113

3.  Visualizing hematopoiesis as a stochastic process.

Authors:  Jason Xu; Yiwen Wang; Peter Guttorp; Janis L Abkowitz
Journal:  Blood Adv       Date:  2018-10-23

4.  Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.

Authors:  Brady L Stein; Donna M Williams; Ophelia Rogers; Mary Ann Isaacs; Jerry L Spivak; Alison R Moliterno
Journal:  Exp Hematol       Date:  2010-10-01       Impact factor: 3.084

Review 5.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08

6.  Mathematical modeling of therapeutic strategies for myeloid malignancies.

Authors:  Dan Wu; Huiyu Li; Wen Du; Xiaoxia Ji; Wei Liu; Shiang Huang; Yi Xiao
Journal:  Pathol Oncol Res       Date:  2012-10       Impact factor: 3.201

7.  Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5.

Authors:  Fulu Liu; Ghada Kunter; Maxwell M Krem; William C Eades; Jennifer A Cain; Michael H Tomasson; Lothar Hennighausen; Daniel C Link
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

Review 8.  Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia--insights from mathematical model analyses.

Authors:  Ingo Roeder; Ingmar Glauche
Journal:  J Mol Med (Berl)       Date:  2007-07-28       Impact factor: 4.599

9.  The landscape of somatic mutations in protein coding genes in apparently benign human tissues carries signatures of relaxed purifying selection.

Authors:  Vinod Kumar Yadav; James DeGregori; Subhajyoti De
Journal:  Nucleic Acids Res       Date:  2016-02-15       Impact factor: 16.971

10.  New experimental and theoretical investigations of hematopoietic stem cells and chronic myeloid leukemia.

Authors:  Ingo Roeder; Mark d'Inverno
Journal:  Blood Cells Mol Dis       Date:  2009-05-02       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.